Trade

with

Sagent Pharmaceuticals Co
(NASDAQ: SGNT)
AdChoices
32.65
-0.10
-0.31%
After Hours :
-
-
-

Open

32.74

Previous Close

32.75

Volume (Avg)

62.70k (226.92k)

Day's Range

32.35-32.84

52Wk Range

17.49-33.60

Market Cap.

1.04B

Dividend Rate ( Yield )

-

Beta

1.66

Shares Outstanding

31.90M

P/E Ratio (EPS)

71.43 (0.46)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 244.75M

    • Net Income

    • 29.59M

    • Market Cap.

    • 1.04B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 5.50

    • PEG (Price/Earnings Growth) Ratio

    • 2.13

    • Beta

    • 1.66

    • Forward P/E

    • 40.49

    • Price/Sales

    • 3.94

    • Price/Book Value

    • 4.23

    • Price/Cash flow

    • 24.39

      • EBITDA

      • 38.49M

      • Return on Capital %

      • 5.37

      • Return on Equity %

      • 7.24

      • Return on Assets %

      • 5.37

      • Book Value/Share

      • 7.73

      • Shares Outstanding

      • 31.90M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 20.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 0.81

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 16.10

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -77.00

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 82.75

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 29.74

            • 64.72

            • Pre-Tax Margin

            • 6.36

            • 13.77

            • Net Profit Margin

            • 5.50

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 14.90

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -30.30

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -30.40

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 4.55

              • 1.52

              • Quick Ratio

              • 3.62

              • 0.87

              • Interest Coverage

              • 14.90

              • 6.77

              • Leverage Ratio

              • 1.25

              • 1.91

              • Book Value/Share

              • 7.73

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 69.93

                • 65.36

                • P/E Ratio 5-Year High

                • 73.49

                • 237.47

                • P/E Ratio 5-Year Low

                • 27.60

                • 19.71

                • Price/Sales Ratio

                • 3.86

                • 3.63

                • Price/Book Value

                • 4.15

                • 3.39

                • Price/Cash Flow Ratio

                • 24.39

                • 21.83

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 7.24

                    (-)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • 5.37

                    (-18.10)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • 7.67

                    (-)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • 54.18k

                  • 27.79k

                  • Inventory Turnover

                  • 3.80

                  • 1.80

                  • Asset Turnover

                  • 0.98

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  31.38M
                  Operating Margin
                  12.82
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  24.39
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  79.17%

                  Mutual Fund Ownership

                  45.66%

                  Float

                  45.26%

                  5% / Insider Ownership

                  2.68%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    1,734,100

                  • 66.20

                  • 5.44

                  • Franklin US Opportunities

                  •  

                    1,145,505

                  • 24.48

                  • 3.59

                  • Franklin Small Cap Growth Fund

                  •  

                    878,300

                  • -14.03

                  • 2.75

                  • Franklin Small-Mid Cap Growth Fund

                  •  

                    866,300

                  • 0.00

                  • 2.72

                  • Franklin Biotechnology Discovery Fund

                  •  

                    773,500

                  • -0.40

                  • 2.43

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    456,995

                  • 0.57

                  • 1.47

                  • Fidelity® Select Pharmaceuticals Port

                  •  

                    417,400

                  • 0.00

                  • 1.31

                  • iShares Nasdaq Biotechnology

                  •  

                    414,619

                  • -0.24

                  • 1.33

                  • SPDR® S&P Pharmaceuticals ETF

                  •  

                    402,222

                  • 0.00

                  • 1.29

                  • Vanguard Small Cap Index

                  •  

                    388,435

                  • 7.63

                  • 1.22

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Advisers, Inc.

                  •  

                    6,286,592

                  • +10.99%

                  • 19.72

                  • Vivo Ventures VI, LLC

                  •  

                    4,180,791

                  • -12.96%

                  • 14.83

                  • Morgan Stanley AIP GP LP

                  •  

                    3,731,292

                  • 0.00%

                  • 11.70

                  • Vivo Ventures V, LLC

                  •  

                    3,618,946

                  • -12.96%

                  • 12.83

                  • BlackRock Fund Advisors

                  •  

                    1,475,464

                  • +71.62%

                  • 4.63

                  • Vanguard Group, Inc.

                  •  

                    1,289,922

                  • +0.90%

                  • 4.05

                  • Sectoral Asset Management Inc

                  •  

                    1,059,306

                  • +2.00%

                  • 3.32

                  • China Renaissance Capital Invest II GP

                  •  

                    1,012,607

                  • -59.51%

                  • 3.19

                  • NWQ Investment Management Co LLC

                  •  

                    802,021

                  • -6.28%

                  • 2.52

                  • State Street Corp

                  •  

                    758,783

                  • +0.68%

                  • 2.38

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Sagent Pharmaceuticals Co is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delawa...morere corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-in...morefective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company’s product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company’s principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.lessless

                  Key People

                  Mr. Jeffrey Yordon

                  CEO/Chairman of the Board/Director

                  Jonathon M. Singer

                  CFO/Executive VP

                  Michael Logerfo

                  Executive VP/Other Executive Officer/Secretary

                  Mr. Albert Patterson, R.Ph.

                  Executive VP, Divisional

                  Mr. Lorin Drake

                  Vice President, Divisional

                  • Sagent Pharmaceuticals Co

                  • 1901 N. Roselle Road

                  • Schaumburg, IL 60195

                  • USA.Map

                  • Phone: +1 847 908-1600

                  • Fax: +1 847 908-1601

                  • sagentpharma.com

                  Incorporated

                  2011

                  Employees

                  269

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: